298 related articles for article (PubMed ID: 30309889)
1. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment.
Gomez-Bougie P; Maiga S; Tessoulin B; Bourcier J; Bonnet A; Rodriguez MS; Le Gouill S; Touzeau C; Moreau P; Pellat-Deceunynck C; Amiot M
Blood; 2018 Dec; 132(25):2656-2669. PubMed ID: 30309889
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
[TBL] [Abstract][Full Text] [Related]
3. BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
S Soderquist R; Eastman A
Mol Cancer Ther; 2016 Sep; 15(9):2011-7. PubMed ID: 27535975
[TBL] [Abstract][Full Text] [Related]
4. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
[TBL] [Abstract][Full Text] [Related]
5. A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R; Descamps G; Bellanger C; Dousset C; Maïga S; Alberge JB; Derrien J; Cruard J; Minvielle S; Lilli NL; Godon C; Le Bris Y; Tessoulin B; Amiot M; Gomez-Bougie P; Touzeau C; Moreau P; Chiron D; Moreau-Aubry A; Pellat-Deceunynck C
Blood; 2024 Mar; 143(13):1242-1258. PubMed ID: 38096363
[TBL] [Abstract][Full Text] [Related]
6. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.
Dai H; Ding H; Meng XW; Peterson KL; Schneider PA; Karp JE; Kaufmann SH
Genes Dev; 2015 Oct; 29(20):2140-52. PubMed ID: 26494789
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
[No Abstract] [Full Text] [Related]
8. Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.
Quentmeier H; Geffers R; Hauer V; Nagel S; Pommerenke C; Uphoff CC; Zaborski M; Drexler HG
Sci Rep; 2022 Jan; 12(1):1085. PubMed ID: 35058488
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA.
Subramanian A; Andronache A; Li YC; Wade M
Oncotarget; 2016 Mar; 7(13):15986-6002. PubMed ID: 26910119
[TBL] [Abstract][Full Text] [Related]
10. Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer.
Liu D; Hou X; Wu W; Zanfagnin V; Li Y; Correia C; Zhao Z; Zhao C; Liu Z; Zhang T; Fang Z; Wang H; Xu C; Weroha SJ; Kaufmann SH; Dai H
Cell Death Dis; 2021 Aug; 12(8):789. PubMed ID: 34385422
[TBL] [Abstract][Full Text] [Related]
11. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
12. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis.
Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M
Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610
[TBL] [Abstract][Full Text] [Related]
13. BCL2 and MCL1 inhibitors for hematologic malignancies.
Roberts AW; Wei AH; Huang DCS
Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
[TBL] [Abstract][Full Text] [Related]
14. Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma.
Jacob M; Wiedemann S; Brücher D; Pieper NM; Birkhold M; Särchen V; Jeroch J; Demes MC; Gretser S; Braun Y; Gradhand E; Rothweiler F; Michaelis M; Cinatl J; Vogler M
Br J Cancer; 2023 Nov; 129(10):1667-1678. PubMed ID: 37723317
[TBL] [Abstract][Full Text] [Related]
15. AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Jia J; Ji W; Saliba AN; Csizmar CM; Ye K; Hu L; Peterson KL; Schneider PA; Meng XW; Venkatachalam A; Patnaik MM; Webster JA; Smith BD; Ghiaur G; Wu X; Zhong J; Pandey A; Flatten KS; Deng Q; Wang H; Kaufmann SH; Dai H
Cell Death Differ; 2024 Apr; 31(4):405-416. PubMed ID: 38538744
[TBL] [Abstract][Full Text] [Related]
16. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors.
Voutsadakis IA
Gene; 2022 Dec; 847():146881. PubMed ID: 36100115
[TBL] [Abstract][Full Text] [Related]
18. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
19. BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic.
Lin VS; Xu ZF; Huang DCS; Thijssen R
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33198338
[TBL] [Abstract][Full Text] [Related]
20. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
